477846-54-1

Basic information

• Product Name: 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE
• Synonyms: 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE
• CAS NO: 477846-54-1
• Molecular Formula: C₁₁H₁₄BrN₃O₂
• Molecular Weight: 300.15
• Mol File: 477846-54-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE(477846-54-1)
• EPA Substance Registry System: 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE(477846-54-1)

Safety Data

• Hazardous Substances Data: 477846-54-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Bromo-4-nitrophenyl)-4-methylpiperazine is used as a building block for the synthesis of various drugs and biologically active molecules due to its unique chemical structure and reactivity. 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE's 2-bromo-4-nitrophenyl group and 4-methylpiperazine moiety provide opportunities for the development of new drugs with improved pharmacological properties.
Used in Research and Development:
In the field of research and development, 1-(2-Bromo-4-nitrophenyl)-4-methylpiperazine is utilized for studying chemical reactions and mechanisms. 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE's reactivity, particularly the bromine and nitro groups, allows for the exploration of various organic synthesis pathways and the creation of novel chemical entities.
Used in Drug Discovery:
1-(2-Bromo-4-nitrophenyl)-4-methylpiperazine plays a significant role in drug discovery, as its unique structure and properties can be leveraged to develop new therapeutic agents. 1-(2-BROMO-4-NITROPHENYL)-4-METHYLPIPERAZINE's potential applications in this area include the development of drugs targeting various diseases and conditions, with a focus on enhancing the efficacy and safety of these treatments.
Overall, 1-(2-Bromo-4-nitrophenyl)-4-methylpiperazine is a versatile compound with a wide range of applications in the pharmaceutical industry, research, and drug discovery. Its unique chemical structure and reactivity make it a valuable asset for the development of new drugs and the study of chemical reactions and mechanisms.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 16588-26-4 3-bromo-4-chloronitrobenzene 
• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 

Downstream Products

• 1352244-28-0 N₂-[3-bromo-4-(4-methylpiperazin-1-yl)phenyl]-5-chloro-N₄-(3-vinylphenyl)pyrimidine-2,4-diamine 
• 477846-55-2 3-bromo-4-(4-methylpiperazin-1-yl)phenylamine 
• 1352244-23-5 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine 
• 1352244-31-5 N₂-[3-bromo-4-(4-methylpiperazin-1-yl)phenyl]-5-chloro-N₄-(2-methoxy-5-vinylphenyl)pyrimidine-2,4-diamine 
• 1352244-32-6 4-bromo-2-(5-chloro-2-[4-(4-methylpiperazin-1-yl)-3-vinylphenylamino]pyrimidin-4-ylamino)benzoic acid methyl ester 
• 1352244-33-7 N₄-[5-bromo-2-(propane-2-sulfonyl)phenyl]-5-chloro-N₂-[4-(4-methylpiperazin-1-yl)-3-vinylphenyl]pyrimidine-2,4-diamine 
• 1352244-34-8 N-(4-bromo-2-{5-chloro-2-[4-(4-methylpiperazin-1-yl)-3-vinylphenylamino]pyrimidin-4-ylamino}phenyl)-N-methylmethanesulfonamide 
• 1352244-80-4 1-methyl-4-(4-nitro-2-vinylphenyl)piperazine 
• 1395029-24-9 1-methyl-4-(4-nitro-2-(prop-1-en-2-yl)phenyl)piperazine 
• 1395028-50-8 3-ethyl-4-(4-methylpiperazin-1-yl)aniline 
• 1395029-25-0 3-isopropyl-4-(4-methylpiperazin-1-yl)aniline 

Relevant articles and documents

The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations

EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of versatile scaffolds suitable for tailored drug development. However not many precedents of this type of pharmacophore have been investigated in the realm of third generation of covalent EGFR-TKIs. Herein, a series of pyrrolo[2,3-d]pyrimidine derivatives able to block mutant EGFR activity in a covalent manner were synthesized, through optimized Buchwald-Hartwig C–N cross coupling reactions. Their preliminary bioactivity and corresponding inhibitory mechanistic pathways were investigated at molecular and cellular levels. Several compounds exhibited increased biological activity and enhanced selectivity compared to the control compound. Notably, compound 12i selectively inhibits HCC827 cells harboring the EGFR activating mutation with up to 493-fold increased efficacy compared to in normal HBE cells. Augmented selectivity was also confirmed by kinase enzymatic assay, with the test compound selectively inhibiting the T790 M activating mutant EGFRs (IC50 values of 0.21 nM) with up to 104-fold potency compared to the wild-type EGFR (IC50 values of 22 nM). Theoretical simulations provide structural evidence of selective kinase inhibitory activity. Thus, this series of pyrrolo[2,3-d]pyrimidine derivatives could serve as a starting point for the development of new EGFR-TKIs.

Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative

The invention provides a pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound shown as a formula I, or a salt t

MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS

The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.

Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.1 9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles

A novel set of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.1 9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to rigidly lock an energy-minimized bioactive conformation of the diaminopyrimidine (DAP) scaffold, a well-documented kinase platform. From 13 analogues prepared, macrocycle 2m showed the most promising in vitro ALK enzymatic (IC50 = 0.5 nM) and cellular (IC50 = 10 nM) activities. In addition, macrocycle 2m exhibited a favorable kinase selectivity preference for inhibition of ALK relative to the highly homologous insulin receptor (IR) kinase (IR/ALK ratio of 173). The inclusive in vitro biological results for this set of macrocycles validate this scaffold as a viable kinase template and further corroborate recent DAP/ALK solid state studies indicating that the inverted "U" shaped conformation of the acyclic DAPs is a preferred bioactive conformation.

Cobalt-catalyzed C-N bond-forming reaction between chloronitrobenzenes and secondary amines

Cyclic secondary amines react with mono- or dichloronitrobenzene in the presence of a catalytic amount of cobalt(II) chloride. Phosphane ligands are beneficial for the reaction, although the bite-angle effect was not strong. The nitro-substituted tertiary amines formed are important as bioactive compounds and can also be intermediates for the synthesis of substituted anilines. This work represents the first cobalt-catalyzed approach to C-N bond-forming reactions involving aromatic chlorides and cyclic secondary amines. The reaction is ortho- and para-selective, with meta-substituted halides being unreactive in this procedure. The first cobalt-catalyzed C-N bond-forming reaction involving aromatic chlorides and cyclic secondary amines is described.The reaction is ortho- and para-selective; meta-substituted halides are unreactive. Copyright